ATAI Investor Presentation Deck

SUMMARY OWNERSHIP 53.8%¹ PRODUCT PHARMA- COLOGY PRODUCT FEATURES INDICATIONS CURRENT STATUS INTELLECTUAL PROPERTY HIGHLIGHT Deuterated etifoxine HCI oral dosage form (GRX-917) Etifoxine facilitates endogenous production of neurosteroids like allopregnanolone through agonist activity at the mitochondrial translocator protein (TSPO) GRX-917 is designed to have rapid onset activity of anxiolytic activity like benzodiazepines but without the sedating, addicting, or cognitive impairing properties Primary: Generalized Anxiety Disorder Potential: Social Anxiety Disorder, Postpartum Depression Phase 1 trial initiated in H1'21 Issued composition of matter on deuterated etifoxine (GRX-917) and corresponding methods of use GRX-917 is aimed to be an improved version of Etifoxine, which already showed promising results 28 GRX-917 has the potential for benzodiazepine-like rapid- onset efficacy with improved safety and tolerability ETIFOXINE HAS BEEN APPROVED FOR ANXIETY DISORDER SINCE 1979 WITH 14M+ PRESCRIPTIONS Etifoxine works as rapidly as lorazepam, with etifoxine continuing its effects beyond treatment, while lorazepam shows rebound Etifoxine has a strong safety record: a review of over 14m prescriptions in France found no cases of abuse, misuse or dependence³ ONGOING PHASE 1 TRIAL Part 1: Single Ascending Dose TREATMENT Up to 40 healthy subjects: Up to 5 cohorts SAFETY/PK/PD PD Endpoint: qEEG Ham-A total score 30 (2) Nguyen et al., "Efficacy of etifoxine compared to lorazepam monotherapy" (2006) (3) Cottin et al., "Safety profile of etifoxine: A French pharmacovigilance survey" (2016) 20 15 5 0 THIRD PARTY STUDY² Non Inferiority Test Day 0 P=0.0001 Day 7 Under treatment P=0.0002 TREATMENT Day 28 Part 2: Multiple Ascending Dose Day 35 Safety Up to 36 healthy subjects: Up to 3 cohorts SAFETY/PK/PD Note: HAM-A = Hamilton Anxiety Rating Scale, SD = standard deviation, qEEG = Quantitative electroencephalography, PK = Pharmacokinetics. PD = Pharmacodynamics. (1) Unless otherwise indicated herein, ownership percentage based on ownership of securities with voting rights as of June 30th, 2022. Etifoxine Lorazepam PD Endpoint: qEEG

View entire presentation